# Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

> clinical trial · VERIFIED · 2026-06-16

Status: RECRUITING · Sponsor: Kite, A Gilead Company · Condition: Relapsed or Refractory Large B-cell Lymphoma

- Company: Kite, A Gilead Company
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07479797

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.